• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
99 results

Dr. Reddy’s Laboratories, Ltd. v. GALDERMA LABORATORIES, INC.

Docket IPR2015-01782, Patent Trial and Appeal Board (Aug. 20, 2015)
Erica Franklin, Robert Pollock, Zhenyu Yang, presiding
Case TypeInter Partes Review
Patent8603506
Orange Book Patent8603506
Petitioner Dr. Reddy’s Laboratories, Ltd.
Patent Owner GALDERMA LABORATORIES, INC.
cite Cite Docket
Analyze

10 Decision Denying Institution: Decision Denying Institution of Inter Partes Review

Document IPR2015-01782, No. 10 Decision Denying Institution - Decision Denying Institution of Inter Partes Review (P.T.A.B. Feb. 16, 2016)
Example 38 of the ’506 patent discloses that in a six-month, placebo- controlled trial for the treatment of acne4 using 20 mg doxycycline hyclate, twice daily, doxycycline-treated patients showed a statistically significant reduction in both comedones and inflammatory lesions (defined as “papules and pustules, less than or equal to 5 nodules”) as compared to placebo.
8 Patent Owner provisionally adopts, as do we, Petitioner’s definition of a person of ordinary skill in the art as “a licensed and practicing dermatologist with as little as one year of treating patients in a hospital, clinical, and/or private setting.” Prelim. Resp. 7; Pet. 25 (both quoting Ex. 1004 ¶ 11).
Golub states that, [i]n several studies on humans, routinely prescribed, antimicrobially-effective doses of tetracyclines ... were found to reduce the collagenase activity in the fluid of the periodontal pocket which originates from the adjacent host tissues.
The current study was carried out to determine whether a newer, semi-synthetic tetracycline, doxycycline, could be administered to humans in a low-dose regimen[,] which would effectively inhibit collagenase activity in the gingival tissue as well as in the crevicular fluid.
Case IPR2015-01782 Patent 8,603,506 B2 tissue type, we note that Golub’s study number one, a “more complex clinical protocol” involving 60 milligrams of doxycycline per day, showed suppressed collagen activity but did not significantly reduce inflammation.
cite Cite Document
Analyze

9 Order: Decision Petitioners Motion for Pro Hac Vice Admission of Evan Diamond 3...

Document IPR2015-01782, No. 9 Order - Decision Petitioners Motion for Pro Hac Vice Admission of Evan Diamond 37 CFR 4210 (P.T.A.B. Dec. 1, 2015)

cite Cite Document
Analyze

4 Notice of Filing Date Accorded to Petition: Notice of Filing Date Accorded to Petitio...

Document IPR2015-01782, No. 4 Notice of Filing Date Accorded to Petition - Notice of Filing Date Accorded to Petition (P.T.A.B. Sep. 2, 2015)

cite Cite Document
Analyze

7 Motion: Galderma Motion for Pro Hac Vice Admission of Evan Diamond IPR2015 ...

Document IPR2015-01782, No. 7 Motion - Galderma Motion for Pro Hac Vice Admission of Evan Diamond IPR2015 01782 (P.T.A.B. Sep. 15, 2015)

cite Cite Document
Analyze

2 Petition: Cover Letter with Exhibit List

Document IPR2015-01782, No. 2 Petition - Cover Letter with Exhibit List (P.T.A.B. Aug. 20, 2015)

cite Cite Document
Analyze

1 Petition: Petition For Inter Partes Review of Claims 1, 7, 8, 14, 15 and 20 of US Pa...

Document IPR2015-01782, No. 1 Petition - Petition For Inter Partes Review of Claims 1, 7, 8, 14, 15 and 20 of US Patent No 8,603,506 (P.T.A.B. Aug. 20, 2015)

cite Cite Document
Analyze

8 Preliminary Response: Patent Owner Preliminary Response

Document IPR2015-01782, No. 8 Preliminary Response - Patent Owner Preliminary Response (P.T.A.B. Nov. 24, 2015)

cite Cite Document
Analyze
1 2 3 4 5 6 7 8 >>